Method and system for developing and querying a sequence driven contextual knowledge base

• US 20040249791A1
• Filed: 06/03/2003
• Published: 12/09/2004
• Est. Priority Date: 06/03/2003
• Status: Abandoned Application

• Current Assignee: Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services
• Original Assignee: Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services
• Inventors: Waters, Michael D., Selkirk, James K., Tennant, Raymond W.
• Application Number:
  US10/452,384
• Publication Number:
  US 20040249791A1
• Time in Patent Office: Days
• US Class Current: 707/3
• CPC Class Codes: G16B 25/00 ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
• CPC Class Codes: G16B 30/00 ICT specially adapted for sequence analysis involving nucleotides or amino acids
• CPC Class Codes: G16B 50/00 ICT programming tools or database systems specially adapted for bioinformatics

Abstract

Disclosed is a method and system of predictive toxicology in the form of a multigenome knowledge base incorporating gene and protein molecular expression analysis, gene/protein functional annotation, domain specific ontologies, and literature mapping. The knowledge base can be globally queried by means of local sequence alignment as well as by any other knowledge base object. This sequence linkage enables continuous refinement of data quality, information documentation, and integration of new knowledge across species. Any molecular expression profile derived experimentally or in the clinic, representing expressed genes, proteins, or partial sequences known to the knowledge base, can be used to globally query the knowledge base to find common concordant expression profiles reflecting specific clinical observations and measurements that have been indexed and context documented in terms of dose, treatment time and phenotypic severity.

Claims

1. A method of querying and receiving information, wherein the method comprises

(a) providing to a query engine a query term;

(b) matching a nucleic acid sequence tag to the query term;

(c) identifying at least one active knowledge template comprising the information described in context and related by the nucleic acid sequence tag; and

(d) returning the information from the active knowledge template.

2. The method of claim 1, wherein the information comprises toxicogenomic information.

3. The method of claim 1, wherein the query term comprises one or more nucleic acid sequences.

4. The method of claim 1, wherein the query term comprises one or more amino acid sequences.

5. The method of claim 1, wherein the active knowledge template comprises data sets for molecular expression assays, experimental protocols for which a biological sample is generated for the molecular expression assays, and phenotypic outcomes resulting from the experimental protocols.

6. The method of claim 5, wherein the active knowledge template comprises data sets for literature pertaining to the data sets.

7. The method of claim 6, wherein the data sets comprise data related to nucleic acid sequences, pharmacology, toxicology, clinical chemistry, histopathology, one or more signal transduction, metabolic, pharmacological or toxicological pathways, gene expression, protein production, molecular interaction (protein-protein or protein-DNA), chemical structure, metabolite synthesis, degradation or elimination, and/or clinical pathology.

8. A computer-readable medium having stored thereon computer-executable instructions for performing the method of claim 1.

9. A method of defining active knowledge templates, wherein the method comprises:

(a) accepting a first set of data;

(b) storing the first set of data;

(c) establishing relationships between the data and one or more nucleic acid sequence tags;

(d) accepting a second set of data; and

(e) modifying relationships between the first data set, the second data set and/or contextual information based on the accepted second data set.

10. The method of claim 9, wherein (d) and (e) are repeated at least once.

11. The method of claim 9, wherein the molecular expression data comprises toxicogenomic data.

12. The method of claim 9, wherein the contextual information comprises data sets for molecular expression assays, experimental protocols for which a biological sample is generated for the molecular expression assays, and phenotypic outcomes resulting from the experimental protocols.

13. The method of claim 12, wherein the active knowledge template comprises data sets for literature pertaining to the data sets.

14. The method of claim 13, wherein the data sets comprise data related to nucleic acid sequences, pharmacology, toxicology, chemical structures, clincal chemistry, histopathology, one or more signal transduction, metabolic, pharmacological or toxicological pathways, gene expression, protein production, molecular interaction (protein-protein or protein-DNA), metabolite synthesis, degradation or elimination, and/or clinical pathology.

15. The method of claim 9, wherein the first data set comprises gene expression data determined by exposure of a microarray comprising oligonucleotide probes or cDNA probes of known sequence to a biological sample, wherein the oligonucleotide probes or cDNA probes are sequence verified and bind to predetermined gene products to produce a detectable signal.

16. The method of claim 15, wherein (c) comprises querying one or more genomic data repositories with a nucleotide sequence of one or more oligonucleotide probes to identify one or more genes corresponding to the one or more oligonucleotide probes via sequence alignment.

17. The method of claim 16, wherein (d) comprises searching literature databases for and nucleic acid sequence tagging scientific literature related to one or more identified genes or one or more products of the identified gene.

18. The method of claim 16, wherein one or more identified genes or one or more products of the identified genes are classified into putative functional groupings.

19. The method of claim 18, wherein one or more identified genes are grouped into signal transduction, metabolic, pharmacological, or toxicological pathways, or histopathological processes.

20. A computer-readable medium having stored thereon computer-executable instructions for performing the method of claim 9.